EMBC - NASDAQ
Embecta Corp.
$3.32
-2.8%Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
At a Glance
Live SnapshotEmbecta Corp. Management Team
Mr. Devdatt Kurdikar Ph.D.
President, Chief Executive Officer & Director
Compensation
$2,337,456
Mr. Jacob P. Elguicze
Senior Vice President & Chief Financial Officer
Compensation
$1,116,259
Ms. Jean M. Casner
Senior Vice President & Chief Human Resources Officer
Compensation
$811,218
Ms. Colleen Riley
Senior Vice President & Chief Technology Officer
Mr. Tom Blount
Senior Vice President & President of North America
Mr. Shaun Curtis
Senior Vice President of Global Manufacturing & Supply Chain
Compensation
$1,034,242
Ms. Ginny Blocki
Senior Vice President of Global Marketing & Product Management
Mr. Jeffrey Z. Mann
Senior Vice President, General Counsel, Head of Business Development & Corporate Secretary
Compensation
$993,198
Mr. Pravesh Khandelwal
Vice President & Head of Investor Relations
Mr. Anthony M. Roth
Vice President, Chief Accounting Officer & Corporate Controller
Embecta Corp. Insider Positioning
During the last 12 months, insiders have sold $11K worth of EMBC shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
916
11.25K
-11K
-$11K
Top Buyers
No buying activity
Top Sellers
Casner Jean
Officer: Chief Human Resources Officer
$11K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $11K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
EMBC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | December 18, 2025 | February 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | December 19, 2024 | February 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | December 19, 2023 | February 07, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | December 30, 2022 | February 09, 2023 | 2023 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.